AA
NAMS icon

ALPS Advisors’s NewAmsterdam Pharma NAMS Stock Holding History

ALPS Advisors’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4M Buy
118,145
+24,549
+26% +$809K 0.02% 340
2026
Q1 		$3M Buy
93,596
+694
+0.7% +$22.6K 0.01% 332
2025
Q4 		$3.26M Buy
+92,902
New +$3.38M 0.02% 314
2025
Q3 		– Sell
-60,551
Closed -$1.1M – 1114
2025
Q2 		$1.1M Sell
60,551
-17,410
-22% -$318K 0.01% 483
2025
Q1 		$1.6M Buy
77,961
+3,252
+4% +$72.3K 0.01% 383
2024
Q4 		$1.92M Buy
74,709
+5,049
+7% +$107K 0.01% 354
2024
Q3 		$1.16M Buy
+69,660
New +$1.21M 0.01% 463

Other funds holding NAMS

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
SAM
SEB Asset Management Stockholm $26.6B AUM
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

ALPS Advisors's NAMS Position: Q2 2026 in Review

ALPS Advisors increased its NewAmsterdam Pharma (NAMS) stake by 26% in Q2 2026, buying an estimated $809K and bringing the position to 118,145 shares worth $4M. The position accounts for 0.02% of the portfolio, ranked #340.

ALPS Advisors first reported a position in NAMS in Q3 2024 and has held it in 7 quarters since. 66 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

  • ALPS Advisors held 118,145 shares of NewAmsterdam Pharma worth $4M as of Q2 2026.
  • ALPS Advisors bought 24,549 NewAmsterdam Pharma shares in Q2 2026, an estimated $809K.
  • NewAmsterdam Pharma made up 0.02% of ALPS Advisors's portfolio in Q2 2026, its #340 holding.
  • ALPS Advisors first reported a position in NewAmsterdam Pharma in Q3 2024 and has held it in 7 quarters since.
  • 66 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.